Mar 24, 2020 / 09:00PM GMT
Operator
Greetings and welcome to the Allakos trial initiation and corporate update. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Robert Alexander, Chief Financial -- Chief Executive Officer. Thank you. You may begin.
Robert Alexander - Allakos Inc. - CEO & Director
Thank you and I'd like to thank everybody for joining our call.
A reminder that I will be making forward-looking statements. So please refer to our most recent regulatory filings, in particular, our 10-K for a broader discussion of our risk factors.
On Slide 3. In terms of agenda, I will go through an overview and then turn it over to Henrik to go through the clinical trials details, and then at the end, we'll have a Q&A.
Okay. So on Slide 5. In terms of an overview, we recently initiated our Phase III study in eosinophilic gastritis and/or eosinophilic duodenitis. We previously referred to this as EGE, but it's simply a name change to be more precise. We also recently initiated a Phase
Allakos Inc. - Special Call Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers